• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

NQO1 Gene Record

  • Summary
  • Interactions
  • Claims
  • NQO1 1728 Druggable Genome

    Alternate Names:

    1728
    NAD(P)H QUINONE DEHYDROGENASE 1
    NQO1
    DHQU
    DIA4
    DTD
    NMOR1
    NMORI
    QR1
    125860
    2874
    ENSG00000181019
    OTTHUMG00000137575
    P15559
    Quinone reductase 1
    Phylloquinone reductase
    NAD(P)H:quinone oxidoreductase 1
    Menadione reductase
    DT-diaphorase
    Azoreductase
    NAD(P)H dehydrogenase [quinone] 1
    PA31744
    NQO1_HUMAN
    T52389

    Gene Info:

    Target Class Enzymes
    Target Subclass EC:1.6.5.5
    Target Subclass 1.6.5.2
    Target Main Class Enzymes
    Gene Biotype PROTEIN_CODING
    (7 More Sources)

    Gene Categories: Category Details

    DRUGGABLE GENOME
    ENZYME

    Publications:

    Ip et al., 2000, Schisandrin B protects against menadione-induced hepatotoxicity by enhancing DT-diaphorase activity., Mol. Cell. Biochem.
    Chiou et al., 1999, DT-diaphorase protects against menadione-induced oxidative stress., Toxicology
    Munday et al., 1999, Effect of butylated hydroxyanisole on the toxicity of 2-hydroxy-1,4-naphthoquinone to rats., Chem. Biol. Interact.
    Munday et al., 1999, Effect of inducers of DT-diaphorase on the toxicity of 2-methyl- and 2-hydroxy-1,4-naphthoquinone to rats., Chem. Biol. Interact.
    Kishi et al., 2002, Effect of dicumarol, a Nad(P)h: quinone acceptor oxidoreductase 1 (DT-diaphorase) inhibitor on ubiquinone redox cycling in cultured rat hepatocytes., Free Radic. Res.
    Nolan KA et al., 2010, In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2)., Bioorg Med Chem Lett
    Ravegnini G et al., 2019, An exploratory study by DMET array identifies a germline signature associated with imatinib response in gastrointestinal stromal tumor., Pharmacogenomics J
    Ross D, 2005, Functions and distribution of NQO1 in human bone marrow: potential clues to benzene toxicity., Chem Biol Interact
    Moffit et al., 2007, Role of NAD(P)H:quinone oxidoreductase 1 in clofibrate-mediated hepatoprotection from acetaminophen., Toxicology
    Asher et al., 2003, P53 hot-spot mutants are resistant to ubiquitin-independent degradation by increased binding to NAD(P)H:quinone oxidoreductase 1., Proc. Natl. Acad. Sci. U.S.A.
    Preusch et al., 1990, Vitamin K1 2,3-epoxide and quinone reduction: mechanism and inhibition., Free Radic. Res. Commun.
    Chen et al., 1999, Molecular characterization of binding of substrates and inhibitors to DT-diaphorase: combined approach involving site-directed mutagenesis, inhibitor-binding analysis, and computer modeling., Mol. Pharmacol.
    Arriagada et al., 2000, Studies of aminochrome toxicity in a mouse derived neuronal cell line: is this toxicity mediated via glutamate transmission?, Amino Acids
    Floreani et al., 2000, Protective action of cardiac DT-diaphorase against menadione toxicity in guinea pig isolated atria., Biochem. Pharmacol.
    Joseph et al., 2000, A unique cytosolic activity related but distinct from NQO1 catalyses metabolic activation of mitomycin C., Br. J. Cancer
    Jaiswal, 2000, Characterization and partial purification of microsomal NAD(P)H:quinone oxidoreductases., Arch. Biochem. Biophys.
    Andreani A et al., 2010, Antitumor activity and COMPARE analysis of bis-indole derivatives., Bioorg Med Chem
    Hariani GD et al., 2014, Application of next generation sequencing to CEPH cell lines to discover variants associated with FDA approved chemotherapeutics., BMC Res Notes
    Wong TW et al., 2000, The decrease of mitochondrial NADH dehydrogenease and drug induced apoptosis in doxorubicin resistant A431 cells., Life Sci
    Vásquez-Vivar J et al., 1997, Endothelial nitric oxide synthase-dependent superoxide generation from adriamycin., Biochemistry
    Korashy et al., 2007, Induction of the NAD(P)H:quinone oxidoreductase 1 by ketoconazole and itraconazole: a mechanism of cancer chemoprotection., Cancer Lett.
    Luo Z et al., 2017, Identification of novel variants associated with warfarin stable dosage by use of a two-stage extreme phenotype strategy., J Thromb Haemost
    Pourgholi L et al., 2016, Gene polymorphisms and the risk of warfarin-induced bleeding complications at therapeutic international normalized ratio (INR)., Toxicol Appl Pharmacol
    Chung JE et al., 2015, Effects of NAD(P)H quinone oxidoreductase 1 polymorphisms on stable warfarin doses in Korean patients with mechanical cardiac valves., Eur J Clin Pharmacol
    Cavallari LH et al., 2011, Association of apolipoprotein E genotype with duration of time to achieve a stable warfarin dose in African-American patients., Pharmacotherapy
    Geng R et al., 2014, Oxidative stress-related genetic polymorphisms are associated with the prognosis of metastatic gastric cancer patients treated with epirubicin, oxaliplatin and 5-fluorouracil combination chemotherapy., PLoS One
    Khrunin AV et al., 2014, Pharmacogenomic assessment of cisplatin-based chemotherapy outcomes in ovarian cancer., Pharmacogenomics
    Jamieson D et al., 2011, Two minor NQO1 and NQO2 alleles predict poor response of breast cancer patients to adjuvant doxorubicin and cyclophosphamide therapy., Pharmacogenet Genomics
    Kolesar JM et al., 2011, The NQO1*2/*2 polymorphism is associated with poor overall survival in patients following resection of stages II and IIIa non-small cell lung cancer., Oncol Rep
    Fagerholm R et al., 2008, NAD(P)H:quinone oxidoreductase 1 NQO1*2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer., Nat Genet
    Siegel D et al., 2001, Rapid polyubiquitination and proteasomal degradation of a mutant form of NAD(P)H:quinone oxidoreductase 1., Mol Pharmacol
    Siegel D et al., 1999, Genotype-phenotype relationships in studies of a polymorphism in NAD(P)H:quinone oxidoreductase 1., Pharmacogenetics
    Moran et al., 1999, A potential mechanism underlying the increased susceptibility of individuals with a polymorphism in NAD(P)H:quinone oxidoreductase 1 (NQO1) to benzene toxicity., Proc. Natl. Acad. Sci. U.S.A.
    Kolesar JM et al., 2002, Evaluation of NQO1 gene expression and variant allele in human NSCLC tumors and matched normal lung tissue., Int J Oncol
  • BENZENE   NQO1

    Interaction Score: 5.89

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15935810


    Sources:
    PharmGKB

  • VATIQUINONE   NQO1

    Interaction Score: 5.89

    Interaction Types & Directionality:
    modulator

    Interaction Info:
    Mechanism of Interaction Quinone reductase 1 modulator
    Direct Interaction yes
    Trial Name EPI-743

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial ChemblInteractions

  • DICUMAROL   NQO1

    Interaction Score: 3.79

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    14634213 2113031 10419545 10949919 10874136 10755406 10683249


    Sources:
    NCI PharmGKB

  • CHEMBL1287866   NQO1

    Interaction Score: 2.94

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21074425


    Sources:
    DTC

  • CHEMBL476968   NQO1

    Interaction Score: 2.94

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21074425


    Sources:
    DTC

  • CHEMBL1288253   NQO1

    Interaction Score: 2.94

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21074425


    Sources:
    DTC

  • CHEMBL1287895   NQO1

    Interaction Score: 2.94

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21074425


    Sources:
    DTC

  • CHEMBL1983317   NQO1

    Interaction Score: 2.94

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21074425


    Sources:
    DTC

  • CHEMBL1288281   NQO1

    Interaction Score: 2.94

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21074425


    Sources:
    DTC

  • CHEMBL1287867   NQO1

    Interaction Score: 2.94

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21074425


    Sources:
    DTC

  • SULFORAPHANE   NQO1

    Interaction Score: 0.84

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20395150


    Sources:
    DTC

  • MENADIONE   NQO1

    Interaction Score: 0.63

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10939639 10614691 10190578 10654840 12069105


    Sources:
    TEND

  • ITRACONAZOLE   NQO1

    Interaction Score: 0.59

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17923278


    Sources:
    NCI

  • WARFARIN   NQO1

    Interaction Score: 0.41

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27740732 27581200 26257249 21923605


    Sources:
    PharmGKB

  • HYDROQUINONE   NQO1

    Interaction Score: 0.35

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10393963


    Sources:
    NCI

  • FLUOROURACIL   NQO1

    Interaction Score: 0.22

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25545243 24533712 21946896 21479364 18511948 11160862 10208650


    Sources:
    PharmGKB

  • OXALIPLATIN   NQO1

    Interaction Score: 0.16

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24924344


    Sources:
    PharmGKB

  • ACETAMINOPHEN   NQO1

    Interaction Score: 0.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17188792


    Sources:
    NCI

  • DOXORUBICIN   NQO1

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10954045 9333325


    Sources:
    PharmGKB

  • IMATINIB   NQO1

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    30237583


    Sources:
    PharmGKB

  • CISPLATIN   NQO1

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12370763


    Sources:
    PharmGKB

  • Ensembl: ENSG00000181019

    • Version: 101_38

    Alternate Names:
    NQO1 Ensembl Gene Name

    Gene Info:
    Gene Biotype PROTEIN_CODING

    Publications:

  • TEND: P15559

    • Version: 01-August-2011

    Alternate Names:
    1728 Entrez Gene Id
    P15559 Uniprot Accession
    NQO1_HUMAN Uniprot Id

    Gene Info:
    Target Subclass 1.6.5.2
    Target Main Class Enzymes

    Publications:

  • TdgClinicalTrial: P15559

    • Version: January-2014

    Alternate Names:
    NQO1 Gene Symbol

    Gene Info:
    Target Class Enzymes
    Target Subclass EC:1.6.5.5

    Publications:

  • PharmGKB: NQO1

    • Version: 18-August-2020

    Alternate Names:
    PA31744 PharmGKB ID

    Gene Info:

    Publications:
    Ross D, 2005, Functions and distribution of NQO1 in human bone marrow: potential clues to benzene toxicity., Chem Biol Interact
    Hariani GD et al., 2014, Application of next generation sequencing to CEPH cell lines to discover variants associated with FDA approved chemotherapeutics., BMC Res Notes
    Pourgholi L et al., 2016, Gene polymorphisms and the risk of warfarin-induced bleeding complications at therapeutic international normalized ratio (INR)., Toxicol Appl Pharmacol

  • TTD: Quinone reductase 1

    • Version: 2020.06.01

    Alternate Names:
    NQO1 TTD Gene Abbreviation
    T52389 TTD Target ID

    Gene Info:

    Publications:
    Gueven N et al., 2013, Therapeutic strategies for Leber's hereditary optic neuropathy: A current update., Intractable Rare Dis Res

  • NCI: NQO1

    • Version: 14-September-2017

    Alternate Names:

    Gene Info:

    Publications:
    Moffit et al., 2007, Role of NAD(P)H:quinone oxidoreductase 1 in clofibrate-mediated hepatoprotection from acetaminophen., Toxicology
    Asher et al., 2003, P53 hot-spot mutants are resistant to ubiquitin-independent degradation by increased binding to NAD(P)H:quinone oxidoreductase 1., Proc. Natl. Acad. Sci. U.S.A.
    Anwar et al., 2002, Interaction of the molecular chaperone Hsp70 with human NAD(P)H:quinone oxidoreductase 1., J. Biol. Chem.

  • DTC: NQO1

    • Version: 02-September-2020

    Alternate Names:

    Gene Info:

    Publications:
    Andreani A et al., 2010, Antitumor activity and COMPARE analysis of bis-indole derivatives., Bioorg Med Chem
    Nolan KA et al., 2010, In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2)., Bioorg Med Chem Lett

  • HingoraniCasas: ENSG00000181019

    • Version: 31-May-2017

    Alternate Names:
    ENSG00000181019 Gene Symbol
    NQO1 Ensembl Id

    Gene Info:

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • ChemblInteractions: DIA4

    • Version: chembl_23

    Alternate Names:
    NMOR1 GENE_SYMBOL
    NQO1 GENE_SYMBOL
    NAD(P)H dehydrogenase [quinone] 1 UNIPROT

    Gene Info:

    Publications:

  • Tempus: NQO1

    • Version: 11-November-2018

    Alternate Names:
    NQO1 Gene Symbol

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

  • Pharos: NQO1

    • Version: 01-February-2022

    Alternate Names:
    NAD(P)H dehydrogenase [quinone] 1 Gene Name
    P15559 UniProt ID

    Gene Info:

    Gene Categories:
    ENZYME

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21